Abstract
Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p <0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p <0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.
| Original language | English |
|---|---|
| Pages (from-to) | 134-139 |
| Number of pages | 6 |
| Journal | Clinical Biochemistry |
| Volume | 41 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Feb 2008 |
Fingerprint
Keywords
- Cardiomyopathy
- Clinical study
- Enzyme immunoassay
- Peptide
- Sensitivity and specificity
- Tachyarrhythmia
ASJC Scopus subject areas
- Clinical Biochemistry
Cite this
Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy. / Matsuura, Hiroko; Murakami, Takashi; Hina, Kazuyoshi; Yamamoto, Keizo; Kawamura, Hiroshi; Sogo, Taiji; Shinohata, Ryouko; Usui, Shinichi; Ninomiya, Yoshifumi; Kusachi, Shozo.
In: Clinical Biochemistry, Vol. 41, No. 3, 02.2008, p. 134-139.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy
AU - Matsuura, Hiroko
AU - Murakami, Takashi
AU - Hina, Kazuyoshi
AU - Yamamoto, Keizo
AU - Kawamura, Hiroshi
AU - Sogo, Taiji
AU - Shinohata, Ryouko
AU - Usui, Shinichi
AU - Ninomiya, Yoshifumi
AU - Kusachi, Shozo
PY - 2008/2
Y1 - 2008/2
N2 - Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p <0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p <0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.
AB - Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p <0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p <0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.
KW - Cardiomyopathy
KW - Clinical study
KW - Enzyme immunoassay
KW - Peptide
KW - Sensitivity and specificity
KW - Tachyarrhythmia
UR - http://www.scopus.com/inward/record.url?scp=38849146408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38849146408&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2007.10.015
DO - 10.1016/j.clinbiochem.2007.10.015
M3 - Article
C2 - 18039472
AN - SCOPUS:38849146408
VL - 41
SP - 134
EP - 139
JO - Clinical Biochemistry
JF - Clinical Biochemistry
SN - 0009-9120
IS - 3
ER -